Chugai Pharmabody Research Pte. Ltd. ("CPR") was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis in Singapore, it aims to generate new antibody drugs based on Chugai's proprietary antibody engineering technologies, such as recycling antibody, sweeping antibody, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development.
MNCJobz.com will not be responsible for any payment made to a third-party. All Terms of Use are applicable.